NCT03440021

Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers

The Effects of Single-dose Administration of a Novel Selective alpha2c Antagonist on Emotional and Cognitive Processing in Healthy Volunteers: an fMRI Investigation

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: University of Cape Town · Academic / Other
• Sex: All
• Age: 18 Years – 30 Years
• Healthy volunteers: Accepted

Summary

The aim of the present study is to investigate changes in neural activity (BOLD signal), as measured using fMRI, in brain areas associated with emotional and working memory during task performance after single-dose administration of a novel selective alpha2c adrenoceptor antagonist (ORM-12741) in healthy volunteers. Further, it will be explored whether ORM-12741 affects connectivity between brain areas in rest, as measured using fMRI, and cognitive performance in the sample under investigation.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	ORM-12741	Novel selective alpha2c adrenoceptor antagonist
DRUG	Placebo	Identical in appearance to experimental drug, not psycho-active

Timeline

• Start date: 2018-03-26
• Primary completion: 2018-12-05
• Completion: 2018-12-06
• First posted: 2018-02-20
• Last updated: 2019-01-10

Locations

1 site across 1 country: South Africa